Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a...
Transcript of Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a...
![Page 1: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/1.jpg)
Avances en el tratamiento hormonal del CPRC sin metástasis
Javier CassinelloHospital Universitario de Guadalajara
![Page 2: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/2.jpg)
• Definición y diagnóstico de CPRC M0 PSA rising
• Historia natural y factores de riesgo de los pacientes con CPRC M0
• Estudios fases III en la población CPRC M0
Agenda
1
![Page 3: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/3.jpg)
• Definición y diagnóstico de CPRC M0 PSA rising
• Historia natural y factores de riesgo de los pacientes con CPRC M0
• Estudios fases III en la población CPRC M0
Agenda
2
![Page 4: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/4.jpg)
• Rising PSA [> 2ng/ml , higher 25% than nadir and confirmed by second PSA at 3 weeks]
• Levels of testosterone < 50 ng/dL or <1.7 nmol/L
• No radiographic evidence of metastatic disease
The Prostate Cancer Clinical Trials Working Group 2 (PCWG2)
The Prostate Cancer Clinical Trials Working Group 3 (PCWG3)
A rising PSA with no detectable disease in the primary site, in bone byradionuclide bone scan or CT or in visceral organs
Nonmetastatic (nmCRPC)
Scher HI. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26:1148-59
Sher HI. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 34:1402-1418.
3
Definición de CPRC M0
![Page 5: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/5.jpg)
PROSTATE CANCER LANDSCAPE AND THERAPIES IN 2018
Scher HI, et al. J Clin Oncol 2016;34:1402-18
ClinicalMetastases: Noncastrate
ClinicallyLocalizedDisease
RisingPSA
Noncastrate
nmCRPC
mCRPC:1st line
mCRPC:2nd line
mCRPC:“n” line
AbirateroneDocetaxel
AbirateroneEnzalutamide
DocetaxelCabazitaxelRadium-223
Castration
NO STANDARD THERAPY
M0
5
30%
10-20%
TDA
4
![Page 6: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/6.jpg)
Scher HI. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26:1148-59
Sher HI. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 34:1402-1418.
5
Número de CPRC M0
M0
100.000 pacientes en USAIncidencia anual de 50-60.000
Sin tratamiento, el 30-50% de estos pacientesCPRC M0 desarrollarán metástasis en lossiguientes 2 años
![Page 7: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/7.jpg)
CPRC M0:
St. Gallen 2015. M0 is an “artificial disease stage designation”.
The definition of M0 is dependent upon the imagen technologychosen”. There is a high likelihood that systemic micro-metastases aremissed by commonly used imaging tools (CT and bone scintigraphy).
– St. Gallen 2015 (77%): In daily clinical practise a negative CTand a negative Bone Scan are suficient for diagnosis of M0disease.
6
Definición “artificial” de CPRC M0
![Page 8: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/8.jpg)
Información Ventajas Limitaciones
GGO Actividad osteoblástica
Cuerpo completo
- Baja Esp- Lesiones líticas
TAC Densidad ósea - Cuerpo completo
- Alta Esp
Lesiones medulares
RM Alteraciones de señal
- Lesiones medulares
- Alta Se
Lesiones corticales
PET
colina
Proliferación celular (carga tumoral)
- Cuerpo completo
- Alta Se
Disponibilidad
1. Wade AA, et al. AJR 2006, 186:1783-86 .2. Talbot JN, et al. Q J Nucl Med Mol Imaging. 2011;55: 374-410.3. Costelloe CM, et al. J Cancer 2010; 1: 80-92.4. WondergemM , et al. Nucl Med Commun. 2013;34:935-45. Review.
Papel de distintas técnicas de imagen en la valoración inicial MO.
7
![Page 9: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/9.jpg)
7
8
![Page 10: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/10.jpg)
Scher HI. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26:1148-59
Sher HI. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 34:1402-1418.
9
Disminución del número de CPRC M0 real con las nuevas técnicas
“M0”PET-colina
PSMA
“M0”
![Page 11: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/11.jpg)
• Definición y diagnóstico de CPRC M0 PSA rising
• Historia natural y factores de riesgo de
los pacientes con CPRC M0
• Estudios fases III en la población CPRC M0
Agenda
10
![Page 12: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/12.jpg)
Prospective data on the natural history of M0 CRPC: phase III trials
11
![Page 13: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/13.jpg)
Risk Factors for Bone Metastases:
comparison of the placebo arms
Supervivencia Libre de Metástasis (SLM): 25-30 m
12
![Page 14: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/14.jpg)
Risk Factors for Bone Metastases:
comparison of the placebo arms
30-40 % de estos pacientes desarrollan metástasis a 2 años
13
![Page 15: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/15.jpg)
Risk Factors for Bone Metastases:
comparison of the placebo arms
Importancia del PSADT 14
![Page 16: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/16.jpg)
Smith MR et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised,placebo-controlled trial. Lancet 2013; 379: 39-46
1.432 CPRC
PSA ≥ 8 ng/mLPSA-DT ≤ 10 meses
Factores de estratificación:
• PSA ≥ 8 ng/mL y PSA-DT ≤ 10 meses (sí o no)
• QT previa o actual para CaP (sí o no)
ALEATORIZACIÓN
1:1
Denosumab 120 mg sccada 4 semanas
N=716
Placebo 120 mg sccada 4 semanas
N=716
Objetivo principal:
• Supervivencia libre de metástasis ósea o muerte
15
![Page 17: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/17.jpg)
Shorter PSA Doubling Time is a Predictor of Increasing Risk for Bone Metastasis and Death
PSA Doubling Time in Months
Rela
tive R
isk f
or
Bo
ne M
eta
sta
sis
or
Death
Median
PSA DT at
study
entry
1.4
1.6
1.8
2.0
2.2
2.4
2.6
2.8
3.0
20 18 16 14 12 10 8 6 4 2
PSA DT
eligibility
criteria
Placebo arm, N = 716
• Placebo arm of the Denosumab study demonstrates shortening PSA doubling time as a
predictor of increasing risk for bone metastases development
• In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤
6 months was significantly associated with shorter bone metastasis-free survival1
Smith et al 16
![Page 18: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/18.jpg)
Shorter PSA Doubling Time is a Predictor of Increasing Risk for Bone Metastasis and Death
PSA Doubling Time in Months
Rela
tive R
isk f
or
Bo
ne M
eta
sta
sis
or
Death
Median
PSA DT at
study
entry
1.4
1.6
1.8
2.0
2.2
2.4
2.6
2.8
3.0
20 18 16 14 12 10 8 6 4 2
PSA DT
eligibility
criteria
Placebo arm, N = 716
• Placebo arm of the Denosumab study demonstrates shortening PSA doubling time as a
predictor of increasing risk for bone metastases development
• In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤
6 months was significantly associated with shorter bone metastasis-free survival1
Smith et al (2005)
17
![Page 19: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/19.jpg)
CPRCM0: 2 types of patients
High risk for rapid progression (and may benefit
from earlier initiation of ADT)
• PSA ≥ 8 ng/ml and
PSADT ≤ 10 months
Observation may be employed if
• Lower PSA levels and
PSADT > 10 months
Smith MR et al. J Clin Oncol. 2013;31(30):3800–6.
18
![Page 20: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/20.jpg)
• Definición y diagnóstico de CPRC M0 PSA rising
• Historia natural y factores de riesgo de los pacientes con CPRC M0
• Estudios fases fases III en la población CPRC M0 de alto riesgo
Agenda
19
![Page 21: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/21.jpg)
20
![Page 22: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/22.jpg)
Nota de prensa estudio ARAMIS
Octubre de 2018
21
![Page 23: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/23.jpg)
Slide 5
Presented By Eric Small at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
22
N= 1.207
![Page 24: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/24.jpg)
Slide 7
Presented By Eric Small at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
23
![Page 25: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/25.jpg)
Slide 8
Presented By Eric Small at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
24
![Page 26: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/26.jpg)
Slide 9
Presented By Eric Small at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
25
![Page 27: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/27.jpg)
Slide 13
Presented By Eric Small at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
26
![Page 28: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/28.jpg)
Slide 17
Presented By Eric Small at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
27
![Page 29: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/29.jpg)
Slide 15
Presented By Eric Small at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
28
![Page 30: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/30.jpg)
Slide 16
Presented By Eric Small at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
29
![Page 31: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/31.jpg)
Slide 21
Presented By Eric Small at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
30
![Page 32: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/32.jpg)
Conclusions
Presented By Eric Small at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
31
![Page 33: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/33.jpg)
Slide 23
Presented By Eric Small at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
32
![Page 34: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/34.jpg)
Slide 25
Presented By Eric Small at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
Estudio SPARTAN
33
![Page 35: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/35.jpg)
PROSPER Study Design
Presented By Maha Hussain at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
34
![Page 36: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/36.jpg)
Baseline Patient Characteristics (N = 1401)
Presented By Maha Hussain at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
35
![Page 37: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/37.jpg)
Primary Endpoint: MFS
Presented By Maha Hussain at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
36
![Page 38: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/38.jpg)
Subgroup Analysis of MFS
Presented By Maha Hussain at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
37
![Page 39: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/39.jpg)
Overall Survival: First Interim Analysis
Presented By Maha Hussain at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
38
![Page 40: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/40.jpg)
Time to PSA Progression
Presented By Maha Hussain at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
39
![Page 41: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/41.jpg)
Time to First Use of New Antineoplastic Therapy
Presented By Maha Hussain at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
40
![Page 42: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/42.jpg)
41
![Page 43: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/43.jpg)
42
![Page 44: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/44.jpg)
43
![Page 45: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/45.jpg)
44
![Page 46: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/46.jpg)
Conclusions
Presented By Maha Hussain at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
45
![Page 47: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/47.jpg)
Estudio PROSPER
46
![Page 48: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/48.jpg)
• 1. Ambos estudios positivos, demostrando que la inhibición precoz (M0) de la señalización androgénica es eficaz
• 2. SG todavía no madura. Numerosos análisis apoyan la asociación entre SLM y SG.
• 3. Los efectos secundarios deben monitorizarse y explicarse de manera adecuada. Esto implica elegir muy bien el tipo de paciente a tratarse con estos agentes.
Conclusiones aceptadas sobre SPARTAN y PROSPER
47
![Page 49: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/49.jpg)
Apalutamida yEnzalutamidaen M0
Apalutamida yEnzalutamidaen M0
49
![Page 50: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/50.jpg)
Opinión positiva EMA nueva indicación enzalutamida en CPRCnm de alto riesgo
url: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002639/smops/Positive/human_smop_001356.jsp&mid=WC0b01ac058001d127. Ultimo acceso 25 sept 2018
Septiembre 2018
50
![Page 51: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/51.jpg)
Aprobación ENZALUTAMIDA EN CPRCnm por la EMA
24Octubre
Mateo J, et al. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol (2018)
La aprobación de apalutamida y enzalutamida por la FDA en CPRC nm es la 1ª aprobación basada en beneficio de MFS en CaP y sienta un precedente para un cambio de paradigma en los ensayos clínicos de CaP
![Page 52: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/52.jpg)
![Page 53: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/53.jpg)
Opinión positiva EMA apalutamida en CPRCnm de alto riesgo
Noviembre 2018
51
![Page 54: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/54.jpg)
• ¿SLM como subrogado de SG en M0?
• Nuevos datos en ASCO Y ESMO 2018
Controversias y nuevos datos
52
![Page 55: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/55.jpg)
• ¿SLM como subrogado de SG en M0?
Controversia
53
![Page 56: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/56.jpg)
MFS
OS
54
![Page 57: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/57.jpg)
55N Engl J Med 2018 (June )
![Page 58: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/58.jpg)
N Engl J Med 2018 (June )56
![Page 59: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/59.jpg)
57
![Page 60: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/60.jpg)
de Almeida, ESMO 2018
66
![Page 61: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/61.jpg)
de Almeida, ESMO 2018
67
![Page 62: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/62.jpg)
• Enzalutamida y apalutamida son nuevos agentes indicados en pacientes CRPC M0 de alto riesgo ( ¡nuevo tratamiento estándar¡)
• El objetivo de Supervivencia libre de Metástasis (SLM) parece adecuado (aceptado por la FDA y EMA en este contexto)
• Buena tolerancia a ambos tratamientos, aunque deben tenerse en cuenta la exposición a largo plazo y las toxicidades específicas de cada agente
CONCLUSIONES
68
![Page 63: Avances en el tratamiento hormonal del CPRC sin metástasis · • In a separate study, PSA was a key risk factor for bone metastasis and a PSADT ≤ 6 months was significantly associated](https://reader033.fdocuments.es/reader033/viewer/2022042104/5e8cdcfe2cbd73751e35aa58/html5/thumbnails/63.jpg)
Gracias por su atención